Chronic obstructive pulmonary disease (COPD) is an inflammatory condition associated with abnormal immune responses, leading to airflow obstruction. Lungs of COPD subjects show accumulation of proinflammatory T helper (Th) 1 and Th17 cells resembling that of autoreactive immune responses. As regulatory T (T reg ) cells play a central role in the control of autoimmune responses and their generation and function are controlled by the adipocytokine leptin, we herein investigated the association among systemic leptin overproduction, reduced engagement of glycolysis in T cells, and reduced peripheral frequency of T reg cells in different COPD stages. These phenomena were also associated with an impaired capacity to generate inducible T reg (iT reg ) cells from conventional T (T conv ) cells. At the molecular level, we found that leptin inhibited the expression of forkhead-boxP3 (FoxP3) and its splicing variants containing the exon 2 (FoxP3-E2) that correlated inversely with inflammation and weakened lung function during COPD progression. Our data reveal that the immunometabolic pathomechanism leading to COPD progression is characterized by leptin overproduction, a decline in the expression of FoxP3 splicing forms, and an impairment in T reg cell generation and function. These results have potential implications for better understanding the autoimmune-like nature of COPD and the pathogenic events leading to lung damage.
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COPD | immunometabolism | leptin | regulatory T cells C hronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease of the lung that causes airflow obstruction. The main cause of COPD in developed countries is tobacco smoking; however, genetic and environmental factors have also been implicated recently in its pathogenesis (1) . Quantitative and qualitative alterations of B cells, cluster of differentiation 4
+ (CD4 + ) T cells, and CD8 + T cells have been observed in both airways and blood of COPD subjects (1, 2) . Recent experimental evidence corroborates the hypothesis that tobacco smoking can generate new self-and foreign epitopes may lead to the activation of an aberrant "autoreactive" immune response. These events lead to generation of proinflammatory T helper 1 (Th1) and Th17 CD4 + T cells in the lung of COPD subjects, resembling that of "proper" autoimmune diseases (3) (4) (5) (6) . In this context, immunopathogenesis of chronic inflammatory diseases and autoimmunity has been associated with both a hyperactivity of autoreactive T cells and the failure of local regulatory mechanisms mainly mediated by regulatory T (T reg ) cells (7, 8) . T reg cells are a subset of CD4 + T cells that express the transcription factor forkhead-box-P3 (FoxP3) and are involved in the maintenance of tolerance to self-antigens and abrogation of autoimmune responses (9) . Compelling experimental evidence suggests that differentiation of T reg cells relies on multiple signals, such as those derived from cytokines (i.e., interleukin 2 [IL-2], transforming growth factor-β [TGF-β]), and signal strength from engagement of the T cell antigen receptor (TCR) and from the costimulatory molecules. Classically, the presence of TGF-β can induce the expression of FoxP3 in CD4 + CD25 − conventional T (T conv ) cells stimulated via strong TCR signaling, which leads to their conversion into inducible T reg (iT reg ) cells (10, 11) . However, cytokines can be dispensable in the generation of human iT reg cells, as fully suppressive iT reg cells can also be generated in vitro by suboptimal/low TCR stimulation of T conv cells in a cytokine-independent manner (12) (13) (14) . In this context, it has been shown that different cellular immunometabolic pathways are able to induce effector or regulatory responses, since distinct metabolic programs are required for the commitment of either effector or T reg cell responses (15, 16) . Indeed, while T reg cells generated in vitro in the presence of TGF-β were shown to rely Significance Chronic obstructive pulmonary disease (COPD) is an inflammatory disease characterized by limitation of expiratory airflow. Cellular and molecular pathways involved in disease pathogenesis are not completely defined. Our study reveals that metabolism and immune response cooperate in COPD pathogenesis and progression. COPD subjects with different disease stages showed progressive increase of systemic leptin, an adipose tissue-derived proinflammatory molecule, that, at high concentrations, impaired the capacity of T cells to engage in glycolysis and to generate regulatory T cells. Thus, the loss of these immunoregulatory circuits during COPD determined the hyperactivation of effector T cells that amplified inflammation, leading to progressive decline of lung function. Understanding these immunometabolic mechanisms can have important implications for monitoring COPD progression and for disease treatment.
mainly on lipid oxidation (17) , recent reports have also shown a major role for glycolysis in the induction and suppressive function of human and mouse T reg cells, given the capacity of the glycolytic enzyme enolase-1 to control the expression of specific FoxP3 splicing variants in human T reg cells (so-called "moonlighting" functions) (14) . Interestingly, in human autoimmunity (i.e., multiple sclerosis, type 1 diabetes), an impaired engagement of glycolysis upon suboptimal TCR stimulation of T conv cells has been observed, and this is associated with a reduced suppressive function and generation of T reg cells (14) . These data suggest that glycolysis also plays an unexplored role in T reg cell induction and function, and that its impairment leads to an unbalanced immune response leading to loss of self-immunological tolerance.
Among environmental factors linked with COPD, nutritional state and overweight have recently been taken into account as promoters of disease pathogenesis (18) . Indeed, adipose tissuederived proinflammatory cytokines could further contribute to the development of the disease, but the molecular mechanisms underlying these events are elusive. Indeed, leptin, whose circulating levels are proportional to body mass index (BMI) and adiposity, are able to boost Th1 and Th17, on the one side, and to reduce proliferation and expansion of antiinflammatory T reg cells, on the other (19) (20) (21) . Leptin is a strong regulator of intracellular glucose metabolism and glycolysis, being among the top-ranked circulating factors, together with insulin, able to increase glucose entrance into the cells, thus suggesting a possible role for immunometabolism of T reg cells in the pathogenesis of COPD (22, 23) . Further, it has recently been shown that plasma leptin concentrations exhibit an inverse correlation with lung function in COPD subjects (24, 25) .
Building on the evidence that a strong relationship among FoxP3 expression, T reg cell induction, and glucose metabolism exists in human immune cells, we aimed at investigating the immunometabolic mechanisms linking leptin overproduction, reduced glucose utilization by T cells with loss of immunological self-tolerance, and chronic inflammation in COPD patients at different disease stages.
Results
Immunometabolic Profiling of COPD Patients Reveals an Increased Systemic Secretion of the Proinflammatory Adipocytokine Leptin That Is Linked with COPD Severity and Deteriorated Lung Function.
To depict the circulating immunometabolic asset and its link with circulating immune cells of COPD subjects, we analyzed several immune cell populations in the peripheral blood of COPD patients staged with parameters of the Global Initiative on Obstructive Lung Disease (GOLD; stages II to IV) and compared them with both never-smoker (NS) and smoker (S) healthy controls. Multiparametric cytofluorimetric analysis showed no statistically significant differences in circulating cellular subsets between control populations and COPD subjects at different GOLD stages (SI Appendix, Table S1 ). This peripheral immunophenotyping was paralleled by measurement of plasma levels of several immunometabolic molecules, such as leptin, resistin, myeloperoxidase (MPO), soluble CD40L (sCD40L), monocyte chemoattractant protein-1 (MCP-1), soluble intercellular adhesion molecule-1 (sICAM-1), and soluble tumor necrosis factor receptor (sTNFr). We found that subjects with moderate COPD (GOLD stage II) had lower plasma leptin (Fig. 1A and SI Appendix, Table S2 ), which increased progressively in GOLD stages III and IV, and that these changes were not linked to differences in BMI and adipocyte mass in COPD stages (Fig. 1A and SI Appendix, Table S2 ). Also, plasma levels of resistin, MPO, sCD40L, and MCP-1 had a similar trend, increasing in parallel with disease severity, although to a lesser extent compared with leptin (SI Appendix, Fig. S1 and Table S2 ). Further, sTNFr plasma levels were higher in subjects with severe COPD (GOLD stage III) compared with healthy controls and subjects with COPD at GOLD II and IV stages (SI Appendix, Fig. S1 and Table S2 ). Finally, sICAM was higher in COPD subjects than in NS healthy subjects and comparable with that observed in S healthy subjects (SI Appendix, Fig. S1 and Table S2 ). In all, the above data reveal peculiar biphasic and oscillatory changes in classical immunometabolic parameters, particularly with leptin concentrations that were reduced at early disease stages compared with different controls and that progressively increased in advanced stages of disease ( Fig. 1A and SI Appendix, Table S2 ). To assess the clinical relevance of plasma leptin changes on lung function in COPD subjects, we correlated its circulating levels with residual forced expiratory volume in 1 s (FEV 1 ), a clinical parameter estimating lung capacity. Interestingly, plasma leptin levels correlated inversely with FEV 1 (Fig. 1B) , as well as resistin and MPO associated with lung function (SI Appendix, Fig. S2 ), while no significant correlation was observed among sCD40L, MCP-1, sTNFr, sICAM-1, and lung function (SI Appendix, Fig.  S2 ). Our results suggest the negative impact of proinflammatory adipocytokines on lung function, with particular emphasis on circulating leptin levels.
High Plasma Leptin Levels Correlate with a Defective Engagement of T Cell Glycolysis and with COPD Severity. T cells engage in glycolysis upon TCR stimulation to sustain proliferation and effector functions, on the one side, but also to induce T reg cells and immune regulation, on the other (14, 26, 27) . To measure the capacity to engage in glycolysis by T cells of COPD subjects, freshly isolated peripheral blood mononuclear cells (PBMCs) from NS healthy control, S healthy control, and COPD subjects at different disease stages were analyzed in the presence or absence of anti-CD3 stimulation in RPMI medium supplemented with 5% plasma from autologous subjects so as to preserve each subject's microenvironmental conditions. Both unstimulated and TCRstimulated T cells from patients with moderate disease (GOLD stage II) had higher basal, post-glucose injection, maximal glycolysis and glycolytic capacity, compared with GOLD III and IV stages (Fig. 2) . Interestingly, the glycolytic rate progressively decreased in COPD subjects at GOLD stage III and GOLD stage IV (Fig. 2 and SI Appendix, Fig. S3 ). We also measured oxygen consumption rate (OCR) as a measure of mitochondrial Plasma levels of leptin in NS healthy subjects, S healthy subjects, and COPD subjects at different GOLD stages. Data are from at least n = 7 subjects, data are expressed as mean ± SEM, and each symbol represents an individual healthy control or COPD subject as indicated. *P < 0.05; **P < 0.01; ***P < 0.001 by 2-tailed Mann-Whitney test. (B) Statistical correlation between plasma leptin levels and FEV 1 as a measure of lung function. Data are from n = 31 subjects with COPD, and each symbol represents an individual COPD subject. r = −0.69, P < 0.0001 by Pearson's correlation.
respiration in the basal condition and during TCR stimulation of PBMCs from NS healthy controls, S healthy controls, and COPD subjects (SI Appendix, Fig. S4 ). OCR was generally impaired in COPD subjects compared with healthy controls, and its trend did not reflect the progressive decline of lung function as per extracellular acidification rate (ECAR) (SI Appendix, Fig. S4 ). All together, these findings indicate that T cell glycolysis declines progressively in advanced phases of disease. To relate these findings to the capacity of leptin to control glucose metabolism, we linked the glycolytic capacity of T cells with plasma leptin concentrations in the different control groups and in COPD subjects. Strikingly, we observed a tendency toward an inverse correlation between glycolytic activity and plasma leptin levels, suggesting that high leptin is linked with a progressive decline in T cell glycolytic capacity ( Fig. 3 A, Left and Right). Of note, this inverse correlation was more evident and highly statistical significant in COPD subjects ( Fig. 3 A, Left and Right): Specifically, in GOLD stage II, where plasma leptin concentrations were <15 ng/mL, we observed higher glycolytic capacity, while COPD subjects at GOLD III and IV stages had plasma leptin levels (15 to 25 ng/mL and >25 ng/mL, respectively) higher than those of the other groups and glycolytic capacity progressively declined ( Fig. 3 A, Right). Thus, high plasma leptin typical of advanced COPD stages impacted negatively on the capacity of T cells to engage in glycolysis.
To ascertain the molecular immunometabolic basis for these findings, we measured glycolysis in healthy individuals during T conv cell activation in the presence of exogenous human recombinant leptin (hrLeptin) to recapitulate in vitro the high leptin levels typical of COPD advanced stages (GOLD III and IV). We found that hrLeptin reduced significantly the engagement of glycolysis in T cells in terms of basal, maximal, and glycolytic capacity ( Fig. 3B and SI Appendix, Fig. S5 ). These data suggest that high leptin concentrations are able to reduce the engagement of glycolysis during T cell activation with anti-CD3/ CD28 stimulation ( Fig. 3B and SI Appendix, Fig. S5 ).
Inverse Correlation Among Plasma Leptin, FoxP3 Splicing Variants, and the Frequency of Peripheral T reg Cells in COPD. We analyzed circulating peripheral T reg (pT reg ) cells in NS healthy subjects, S healthy subjects, and COPD subjects at different stages of disease. We stained pT reg cells by using 2 specific FoxP3 monoclonal antibodies (mAbs): one that recognizes FoxP3 protein containing all splicing variants of FoxP3 (defined as CD4 
FoxP3-E2
+ T reg cells), a splicing form recently discovered as pivotal in conferring suppressive ability to T reg cells (14, (28) (29) (30) . Cytofluorimetric analysis revealed that COPD subjects at GOLD stage II had a higher number of both CD4 + FoxP3-all + and CD4 + FoxP3-E2 + pT reg cells compared with healthy subjects (Fig. 4 A, Upper and Lower); however, the frequency of both CD4
+

FoxP3
+ T reg cell subsets progressively decreased in patients with COPD at GOLD stages III and IV ( 
FoxP3-E2
+ pT reg cells was negatively associated with plasma leptin levels ( Fig. 4 B, Left and Right). Among the additional circulating molecules analyzed in COPD subjects, we found that only sTNFr had a significant inverse correlation with the frequency of CD4 Table S3 ). In addition, we measured the expression of the main T reg cellassociated suppressive markers (i.e., CTLA-4, PD-1) and proliferative rate (as Ki-67 staining) in both CD4 For A and B, data are from n = 7 independent experiments (at least n = 2 subjects in 3 technical replicates), and are expressed as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by 2-tailed Mann-Whitney test.
with healthy subjects, patients with COPD at GOLD stage III, and patients with COPD at GOLD stage IV (Fig. 5 , Upper and Lower and SI Appendix, Fig. S8 ). All together, these findings indicate that the frequency of pT reg cells and the expression of their regulatory markers are higher in COPD subjects in the initial stage and progressively decline during disease progression; this decline correlated inversely with plasma leptin concentrations, thus linking leptin secretion and T reg cell frequency and phenotype in COPD.
Leptin Inhibits Induction of iT reg Cells and Negatively Impacts COPD Progression. We explored the efficiency of induction and the suppressive capacity of iT reg cells in healthy and COPD subjects. Flow-sorted CD4 + T conv cells from healthy and COPD subjects were stimulated in vitro to obtain iT reg cells, as previously described (14) (also shown in the schematic model in SI Appendix, Fig. S9 ). We found that the capacity to differentiate into iT reg cells was higher in subjects at GOLD stage II compared with the other groups analyzed (Fig. 6 A, Upper and Lower). On the contrary, the frequency of induction of iT reg cells in the late stages of the disease (GOLD stages III and IV) was lower compared with that of healthy controls (Fig. 6 A, Upper and Lower). Also, FoxP3-all and FoxP3-E2 induction in iT reg cells of COPD subjects correlated with a measure of preserved lung function, such as FEV 1 (Fig. 6 B, Left and Right). Finally, iT reg cell-associated markers (CTLA-4 and PD-1) and Ki-67 on both induced FoxP3-all + and FoxP3-E2 + cells were higher in moderate COPD (GOLD stage II), while they were significantly decreased in COPD at GOLD stages III and IV ( Fig. 7 and SI Appendix, Fig. S10 ). Parallel measurement of cytokines and chemokines released during induction of iT reg cells from TCRstimulated T conv cells revealed that COPD subjects secreted significantly higher amounts of proinflammatory cytokines, such as granulocyte/macrophage colony-stimulating factor, interferon-γ, IL-2, IL-8, IL-17A, tumor necrosis factor-α, interferon-gammainducible protein-10, MCP-1, and monokine induced by gamma interferon, compared with healthy subjects (SI Appendix, Fig. S11 ), while macrophage inflammatory protein 1-α levels were reduced in COPD subjects (SI Appendix, Fig. S11 ). To link these findings with leptin overproduction during COPD progression, and given the negative correlation among plasma leptin, lung function (measured as FEV 1 ), and pT reg cell frequency (Figs. 1B and 4B, respectively), we also correlated plasma leptin concentrations with the frequency of FoxP3-all and FoxP3-E2 induction in iT reg cells from COPD subjects. Once again, we confirmed that there was an inverse correlation between plasma leptin levels and efficiency in induction of iT reg cells in COPD (Fig. 8A) . Among the other circulating molecules, we found that plasma levels of resistin and MCP-1 had an inverse correlation with the percentage of FoxP3-E2
+ and FoxP3-all/E2 + iT reg cells, respectively (SI Appendix, Table  S4 ). On the contrary, sICAM-1 had a significant positive correlation with the percentage of both FoxP3-all + and FoxP3-E2 + iT reg cells (SI Appendix, Table S4 ).
To prove a direct link between leptin and FoxP3 induction, we cultured T conv cells from healthy controls in the presence of exogenous hrLeptin or in the presence of neutralizing antileptin mAb. Interestingly, we found that while hrLeptin impaired the induction of both FoxP3-all and FoxP3-E2 proteins, leptin neutralization, with leptin mAbs, increased their expression (Fig.  8B) . Further, hrLeptin treatment induced a down-regulation of T reg cell-associated markers in iT reg cells, such as CTLA-4 and PD-1, which was associated with a reduced proliferation of iT reg cells expressed as Ki-67 staining (SI Appendix, Fig. S12) Plasma leptin levels <15 ng/ml Plasma leptin levels 15-25 ng/ml Plasma leptin levels >25 ng/ml differentiation increased the expression of the above markers, particularly in FoxP3-E2 + iT reg cells (SI Appendix, Fig. S12 ). In all, these results suggest that leptin directly affects iT reg cell induction in vitro, thus contributing to a deteriorated lung function in COPD subjects.
Progressive Decline of Suppressive Function of iT reg Cells during COPD Progression. Next, we examined whether an impaired induction of iT reg cells observed in COPD subjects was also associated with a deteriorated suppressive function in vitro. The iT reg cells were flow-sorted on the basis of cell surface expression of the T cell activation marker CD25 (a schematic model of experimental procedures is shown in SI Appendix, Fig. S13 ). In 5% autologous plasma, we assessed the ability of iT reg cells from both control and COPD subjects to suppress proliferation of activated CD4 + T cells labeled with the division-tracking dye 5,6-carboxyfluoresceindiacetate-succinimidyl ester (CFSE) in vitro. According to FoxP3-all and FoxP3-E2 amount and leptin levels, flow-sorted iT reg cells from COPD subjects at GOLD stage II showed higher suppressive activity compared with healthy subjects, GOLD stage III subjects, and GOLD stage IV subjects (Fig. 9A) , while iT reg cells from COPD subjects at GOLD stage IV had the lowest suppressive capacity in vitro compared with the controls and the subjects with other GOLD stages (Fig. 9 ). This decline of iT reg cell function paralleled disease progression (Fig. 9B) . In all, our data reveal that not only the efficiency in iT reg cell induction but also the suppressive function of iT reg cells is impaired in COPD subjects, and both phenomena are linked with high leptin production in advanced COPD stages.
Discussion
In this study, we linked systemic metabolic status, through leptin overproduction, with a reduced frequency of pT reg cells and an *** impaired capacity of T conv cells to differentiate into iT reg cells in subjects with different disease stages of COPD. Unbalanced leptin overproduction was independent of an increased BMI and adipocyte mass, and correlated with a progressive loss of lung function. Interestingly, leptin secretion was biphasic over time throughout COPD GOLD stages; indeed, a significant reduction in plasma leptin production occurred at the moderate disease stage (GOLD II), followed by a consistent increase at the late severe disease stages (GOLD III to IV). These events correlated negatively not only with pT reg cell frequency but also with reduced surface expression of T reg cell-specific antiinflammatory markers, such as PD-1 and CTLA-4. We also associated these findings with deteriorated lung function in terms of FEV 1 , typical of advanced COPD stages. Mechanistically, our results were secondary to a reduced capacity of T cells from COPD subjects to engage in glycolysis during TCR stimulation, similar to what has been observed in other chronic inflammatory disorders, such as multiple sclerosis, type 1 diabetes, and glycogen storage disease-1b (14, 30, 31) . The key factor leading to progressive deterioration of T cell glycolytic function was induced by leptin itself. Indeed, while at physiological concentrations (between 5 and 15 ng/mL), leptin increases glucose uptake by T cells (22) , and in conditions in which its levels rise particularly high (>25 ng/mL), it is able to significantly inhibit engagement of glycolysis and consequently reduce the capacity of T conv cells to differentiate into iT reg cells; these effects were also associated with a direct inhibition of FoxP3 gene expression by leptin (Fig.  8B) . These results fit with our COPD model (SI Appendix, Fig.  S14 ) and unveil an immunometabolic determinant leading to progressive loss of lung function during COPD. Specifically, when leptin levels were lower in moderate GOLD stage II (<15 ng/mL), engagement of glycolysis was maintained and the frequency and induction of T reg cells were preserved. On the contrary, when leptin levels reached high concentrations, like in GOLD III and IV advanced stages (15 to 25 ng/mL and >25 ng/mL, respectively), glycolysis progressively deteriorated, and the frequency and induction of T reg cells were also reduced significantly. These events might induce lung damage, exacerbation of inflammation, and loss of lung function as a consequence of dysregulated CD4 + effector functions (SI Appendix, Fig. S14 ). Further, our comprehensive analysis of FoxP3 splicing variants expressed by T reg cells revealed that T reg cell regulatory activities are also impaired during progression of COPD, and are linked inversely with leptin secretion. Interestingly, leptin secretion in this context is disjoined from the adipocyte mass, as BMI did not differ significantly in our COPD study populations, despite the increase in plasma leptin in advanced COPD stages. This evidence suggests that the increased leptin secretion relied mainly on the inflammatory state, determining the loss of its direct correlation with BMI typical of normal-weight healthy subjects. We hypothesize intralung leptin production by inflammatory immune cells (i.e., produced by activated T cells), which have been shown to be capable of producing leptin in inflammatory lesions (21) . This hypothesis clearly needs further investigation, despite the obvious difficulties in obtaining biopsies from COPD subjects at different GOLD stages.
Building on the above evidence that a strong relationship among glucose metabolism, FoxP3 induction, and regulatory function exists in human T cells, we aimed at investigating the molecular mechanisms linking the pathogenesis of COPD, reduced glucose utilization by T cells, and chronic proinflammatory exposure to cigarette smoke (CS). In this context, leptin, a cytokine-like hormone mainly secreted by adipocytes, has been shown to play a significant role in the pathogenesis of several autoimmune disorders, as it boosts Th1/Th17 proinflammatory responses and inhibits proliferation of T reg cells (19, 32) . It has also been reported that increased leptin levels show an inverse correlation with T reg cell frequency in multiple sclerosis, a chronic inflammatory disease of the central nervous system (32) . We show herein a direct capacity of leptin to inhibit FoxP3 induction and iT reg cell differentiation also in the context of a chronic inflammatory disease such as COPD. These results are in agreement with a recent report showing that microenvironmental stimuli produced by the release of cytokines during COPD progression lead to a Th17/T reg cell imbalance in a mouse model of CS-induced disease (33) . However, additional investigations are required to unveil whether leptin is able to affect FoxP3 splicing variants and the epigenetic landscape in human T conv cells, thus modifying their capability to differentiate into iT reg cells. Unfortunately, available mouse models of CS-induced disease have several limitations due to the reduced genetic variability of the inbred strains; the lack of FoxP3 splicing isoforms; 
FoxP3-E2
+ (Lower) cells in NS healthy subjects; S healthy subjects; and COPD subjects at GOLD II, GOLD III, and GOLD IV stages. Data are from at least n = 3 subjects, and are expressed as mean ± SEM. Each symbol represents an individual healthy or COPD subject as indicated. *P < 0.05; **P < 0.01 by 2-tailed Mann-Whitney test.
and the reduced exposure to other pathogenic determinants, such as pollutants, organic dust, lifestyle, and infections (34, 35) . Our results also show biphasic behavior in the axis linking leptin secretion-T reg cell frequency/induction and lung function (a schematic model is shown in SI Appendix, Fig. S14 ). In agreement with our model, it has been shown that plasma leptin inversely correlated with lung function in COPD subjects (24, 25) . Moreover, increased numbers and functions of iT reg cells observed in subjects at the moderate stage (GOLD II) of disease may represent an early compensatory mechanism that counteracts the immune dysregulation induced by inflammatory stimuli (CS or other lung irritants) in the first phase of disease. Both CD4 + FoxP3-all + and CD4 + FoxP3-E2 + T reg cells of COPD patients at the GOLD II stage showed higher proliferative rate measured as Ki-67 staining, compared with other groups analyzed. These findings could also explain the impairment of the T cell-mediated immune response against nontypeable Haemophilus influenzae observed in patients affected by moderate COPD (36) . In agreement with this evidence, the up-regulation of T reg cell subsets observed in S healthy subjects with normal lung function (compared with NS healthy subjects) may be interpreted as an early challenge to regulate the inflammatory response elicited by tobacco smoking. Consistent with this idea, the presence of excessive and prolonged inflammatory stimuli may determine a transitory hyperactivity of T reg cells followed by an "exhaustion" of suppressive activity that relied on a reduced expression of FoxP3-E2 variants as observed in the late stages of disease. The loss of these regulatory mechanisms leads to hyperactivation of CD4 + T conv cell effector functions (a schematic model is shown in SI Appendix, Fig. S14 ) associated with leptin overproduction that amplifies inflammation in COPD, thus determining the progressive decline of lung function and emphysematous condition. Also, these findings are in line with experimental evidence indicating that subjects affected by COPD exhibit many of the characteristics of a classical autoimmune-like response, suggesting that COPD is a multifactorial disorder with a strong autoimmune component (6, 37, 38) . In summary, impaired T reg cell properties and FoxP3 splicing form expression during COPD progression underscore the relevance of these molecular determinants in disease pathogenesis. These factors find their pathomechanism in a progressive and biphasic increase of systemic leptin secretion that impairs the capacity of T cells to engage in glycolysis after suboptimal TCR and FoxP3-E2 + (Lower) cells from NS healthy subjects;
S healthy subjects; and COPD subjects at GOLD stage II, GOLD stage III, and GOLD stage IV, as indicated, are shown. Data are from at least n = 5 subjects, and are expressed as mean ± SEM. Each symbol represents an individual healthy or COPD subject as indicated. *P < 0.05; **P < 0.01; ***P < 0.001 by 2-tailed Mann-Whitney test. stimulation. These phenomena are associated with a reduced pT reg cell frequency in the periphery and an impaired capacity of T conv cells to induce expression of FoxP3. These data also reveal the immunometabolic cues leading to the inflammatory status and the deteriorated lung function that characterize COPD progression. A better understanding of these cellular and molecular mechanisms can provide novel means for immunometabolic treatments during COPD, as well as the identification of biomarkers that might have the potential to monitor and anticipate disease progression over time.
Methods
Additional methods are provided in SI Appendix, Supplementary Materials and Methods.
Study Population. COPD patients were clinically stable with no exacerbation in the previous 3 mo from the blood draw. All of them were being treated with inhaled long-acting bronchodilators, with 51% of patients receiving an association of long-acting muscarinic antagonists and long-acting betaagonists, and 20% of patients also receiving an inhaled steroid. No patients were using oral steroids. Subjects with atopy-related respiratory disorders (allergic rhinitis or asthma) and those taking oral cholesterol or statins or suffering from decompensated diabetes were excluded from the study. Most prevalent comorbidities included systemic arterial hypertension (56%), chronic ischemic heart disease (21%), and type II diabetes (14%). Age-and sex-related healthy volunteers with normal lung function were included as a control group. Blood samples from COPD and healthy subjects were collected at 8:00 AM into heparinized Vacutainer tubes (BD Biosciences) and were processed within the following 4 h. Demographic and clinical features of the study population are reported in SI Appendix, Table S5 .
iT reg Cell Induction. For the generation of iT reg cells, after Ficoll-Hypaque gradient centrifugation (GE Healthcare), T conv cells were isolated from PBMCs by negative selection with a human CD4
cell purity > 98%), and cells were cultured (2 × 10 6 cells per milliliter) in 6-well plates (Falcon; BD Biosciences) with RPMI-1640 medium supplemented with 100 international units (IU)/mL penicillin, 100 μg/mL streptomycin (Life Technologies), and either 5% autologous plasma or 5% AB human serum (Euroclone). Cells were stimulated for 36 h with Dynabeads coated with mAb to CD3 plus mAb to CD28 (Invitrogen) at a density of 0.1 bead per cell. Then, stimulated T conv cells were stained with the following mAbs: phycoerythrinCy7 anti-human CD25 and allophycocyanin-H7 anti-human CD4. Cells were sorted by flow cytometry on the basis of their cell surface expression of CD25 (purity > 98%) with a BD FACSJazz instrument (BD Biosciences) (14) . II III IV  COPD GOLD   II III IV  COPD GOLD   II III IV  COPD GOLD   II III Data are from n = 3 independent experiments (at least n = 2 subjects in 2 technical replicates), and are expressed as mean ± SEM. *P < 0.05; ***P < 0.001; ****P < 0.0001 statistical significance between COPD at GOLD stage II and healthy (NS and S) controls. # P < 0.05 statistical significance between COPD patients at GOLD stage II and NS subjects by 2-way ANOVA corrected for multiple comparisons Tukey test.
§ P < 0.05 statistical significance between COPD patients at GOLD stage IV and S subjects by 2-way ANOVA corrected for multiple comparisons Tukey test. (B) Scatter plots with bar histograms show comparison of suppression ability exerted by iT reg cells (at the indicated ratio) isolated from COPD subjects on proliferation of CFSE-labeled CD4 + T cells stimulated for 72 h in vitro with α-CD3/CD28. Data are from n = 3 independent experiments (at least n = 2 COPD subjects in 2 technical replicates), and are expressed as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by 2-tailed Mann-Whitney test.
alone or with different numbers of iT reg cells (ratios from 1:1 to 8:1; CFSE + CD4 + T cells/iT reg cells) in round-bottomed, 96-well plates (all from Becton Dickinson) (14) . All tests were performed in the presence of RPMI-1640 medium supplemented with 100 IU/mL penicillin, 100 μg/mL streptomycin (Life Technologies), and heat-inactivated 5% autologous plasma. CFSE dilution analysis was performed by gating on CFSE Study Approval. The study was approved by the Institutional Review Board of the University of Naples "Federico II." Healthy and COPD subjects were recruited at the Dipartimento di Medicina Clinica e Chirurgia, Università degli Studi di Napoli "Federico II," and written informed consent was received from participants before inclusion in the study.
